Phase I study of the sequential administration of S-1 and cisplatin for metastatic gastric cancer

Anticancer Research

Volumn 29, Issue 5, 2009, Pages 1727-1732

  Baba, Eishi ^a   Fujishima, Hiromitsu ^b   Kusaba, Hitoshi ^a   Esaki, Taito ^c   Ariyama, Hiroshi ^c   Kato, Ken ^a   Tanaka, Risa ^d   Mitsugi, Kenji ^d   Shibata, Yoshihiro ^a   Harada, Mine ^a   Nakano, Shuji ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KAGOSHIMA MEDICAL CENTER   (Japan)

^c NATIONAL KYUSHU CANCER CENTER   (Japan)

^d HAMANOMACHI HOSPITAL   (Japan)

Author keywords

CDDP; Combination chemotherapy; Metastatic gastric cancer; Phase I study; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN;

ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG FATALITY; FATIGUE; HUMAN; MAXIMUM TOLERATED DOSE; METASTASIS; MULTICENTER STUDY; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; STOMACH CANCER; STOMATITIS;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; OXONIC ACID; STOMACH NEOPLASMS; TEGAFUR;

EID: 67650091229     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA and Rausch M: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72: 37-41, 1993. (Pubitemid 23182046)
2. Glimelius B, Hoffman K, Haglund U, Nyrén O and Sjödén PO. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 5: 189-190, 1994. (Pubitemid 24062577)
3. Pyrhönen S, Kuitunen T, Nyandoto P and Kouri M: Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71: 587-591, 1995.
4. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H and Yoshida S; Japan Clinical Oncology Group Study (JCOG9205). Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable advanced gastric cancer: Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 21: 54-59, 2003.
5. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K and Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two modulators. Anticancer Drugs 7: 548-557, 1996. (Pubitemid 26276346)
6. Chollet P, Schöffski P, Weigang-Köhler K, Schellens JH, Cure H, Pavlidis N, Grünwald V, De Boer R, Wanders J and Fumoleau P; EORTC Early Clinical Studies Group. Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer: A trial performed by the EORTC early clinical studies group (ECGS). Eur J Cancer 39: 1264-1270, 2003. (Pubitemid 36579198)
7. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y and Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur 0.4 M gimestat 1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34: 1715-1720, 1998. (Pubitemid 28474225)
8. Koizumi W, Kurihara M, Nakano S and Hasegawa K: Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 58: 191-197, 2000. (Pubitemid 30189900)
9. Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, Shirao K, Matsumura Y and Gotoh M: Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 89: 2207-2212, 2003. (Pubitemid 38168001)
10. Nakahara H, Takiuchi H, Tsujinaka T, Furukawa H and Taguchi T: Phase I study of CPT-11 plus S-1 in patients with metastatic gastric cancer. Proc Am Soc Clin Oncol Abstr 21: 677, 2002.
11. Yamaguchi K, Shimamura T, Hyodo I, Koizumi W, Doi T, Narahara H, Komatsu Y, Kato T, Saitoh S, Akiya T, Munakata M, Miyata Y, Maeda Y, Takiuchi H, Nakano S, Esaki T, Kinjo F and Sakata Y: Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. Br J Cancer 94(12): 1803-1808, 2006.
12. Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, Todo S, Terashima M, Gotoh M, Sakamoto J and Nishiyama M: PhaseII study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 12(11): 3402-3407, 2006.
13. Esaki T, Nakano S, Tatsumoto T, Kuroki-Migita M, Mitsugi K, Nakamura M and Niho Y: Inhibition by 5-fluorouracil of cis-diamminedichloroplatinum(II)- induced DNA interstrand cross-link removal in a HST-1 human squamous carcinoma cell line. Cancer Res 52(23): 6501-6506, 1992.
14. Kuroki M, Nakano S, Mitsugi K, Ichinose I, Anzai K, Nakamura M, Nagafuchi S and Niho Y: In vivo comparative therapeutic study of optimal administration of 5-fluorouracil and cisplatin using a newly established HST-1 human squamous carcinoma cell line. Cancer Chemother Pharmacol 29(4): 273-276, 1992.
15. Ajani JA, Lee FC, Singh DA, Haller DG, Lenz HJ, Benson AB 3rd, Yanagihara R, Phan AT, Yao JC and Strumberg D: Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24: 663-667, 2006.
16. Dabholkar M, Vionnet J, Bostick-Braton F, Yu JJ and Reed E: Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 94: 703-708, 1994.
17. Fujishima H, Nakano S, Masumoto N, Esaki T, Tatsumoto T, Kondo T and Niho Y: Inhibition by 5-fluorouracil of ERCC1 and gamma-glutamylcysteine synthetase messenger RNA expression in a cisplatin-resistant HST-1 human squamous carcinoma cell line. Oncol Res 9(4): 167-172, 1997.
18. Esaki T, Nakano S, Masumoto N, Fujishima H and Niho Y: Schedule-dependent reversion of acquired cisplatin resistance by 5-fluorouracil in a newly established cisplatin-resistant HST-1 human squamous carcinoma cell line. Int J Cancer 65(4): 479-484, 1996. (Pubitemid 26083256)
19. Peters GJ, Noordhuis P, Van Groeningen CJ, Giaccone G, Holwerda U, Voorn D, Schrijvers A, Schornagel JH, Beijnen JH, Fumoleau P and Schellens JH: The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors. Clin Cancer Res 20: 4072-4076, 2004. (Pubitemid 38812484)
20. Ajani JA, Faust J, Ikeda K, Yao JC, Anbe H, Carr KL, Houghton M and Urrea P: Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 23: 6957-6965, 2005. (Pubitemid 46260282)
21. Sato Y, Kondo H, Honda K, Takahari D, Sumiyoshi T, Tsuji Y, Yoshizaki N and Niitsu Y: A phase I/II study of S-1 plus cisplatin in patients with advanced gastric cancer: 2-week S-1 administration regimen. Int J Clin Oncol 10: 40-44, 2005. (Pubitemid 40379494)
22. Boku N, Yamamoto S, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Kimura A and Ohtsu A: Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). Proc Am Soc Clin Oncol Abstr 25: LBA4513, 2007.
23. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H and Takeuchi M: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9: 215-221, 2008.
24. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Marabotti C and Van Cutsem E; V-325 Study Group: Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol 25(22): 3205-3209, 2007. (Pubitemid 47333732)
25. Ridwelski K, Fahlke J, Kettner E, Schmidt C, Keilholz U, Quietzsch D, Assmann M, Stauch M, Zierau K and Lippert H: Docetaxel-cisplatin (DC) versus 5-fluorouracil-leucovorin-cisplatin (FLC) as first-line treatment for locally advanced or metastatic gastric cancer: Preliminary results of a phase III study. Proc Am Soc Clin Oncol Abstr 26: 4512, 2008.
26. Jin M, Lu H, Li J, Shen L, Chen Z, Shi Y, Song S, Qin S, Liu J and Ouyang X: Randomized 3-armed phase III study of S-1 monotherapy versus S-1/CDDP (SP) versus 5-FU/CDDP (FP) in patients (pts) with advanced gastric cancer (AGC): SC-101 study. Proc Am Soc Clin Oncol Abstr 26: 4533, 2008.
27. Bang Y, Chung H, Sawaki A, Xu J, Shen L, Lipatov O, Park SR, Gangadharan VP, Advani SH and Kang YK: HER2-positivity rates in advanced gastric cancer (GC): Results from a large international phase III trial. Proc Am Soc Clin Oncol Abstr 26: 4526, 2008.